跳至主要内容
临床试验/NCT03949985
NCT03949985已完成不适用

Longitudinal Hemostatic Profile After Stopping Estroprogestative Contraceptives: a Prospective Cohort Study

University Hospital, Geneva1 个研究点 分布在 1 个国家目标入组 103 人开始时间: 2018年10月8日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
103
试验地点
1
主要终点
Change in normalized APC sensitivity ratio

研究概览

简要总结

This prospective cohort evaluates the longitudinal profile of hemostatic biomarkers during the first 3 months after having stopped a combined oral contraceptive.

详细描述

Women using a combined oral contraceptive (COC) and who have decided to stop it or switch it to a non-estrogenic contraceptive are included. At baseline, before the COC is stopped, and at multiple time points during the 3 months of follow-up, blood will be drawn to evaluate the hemostatic profile. Findings are compared with a control group of women without an estrogenic contraceptive, who are also followed for 3 months.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • 18-50 years
  • current use (for at least 3 months) of an estrogenic contraceptive with the decision to stop it or replace it with a non-estrogenic contraceptive (estrogen group)
  • no current use of an estrogenic contraceptive (control group)

排除标准

  • personal history of VTE
  • known thrombophilia
  • recent medical event (hospitalization, surgery, cancer)
  • pregnancy, post-partum period, current breastfeeding

结局指标

主要结局

Change in normalized APC sensitivity ratio

时间窗: Three months

次要结局

  • Change in individual coagulation factors(Three months)
  • Change in concentrations of sex hormone-binding globulin(Three months)
  • Change in fibrinolysis assay(Three months)
  • Contraception-related satisfaction(Three months)
  • Change in Endogenous Thrombin Potential (Thrombin Generation Assay)(Three months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Marc Blondon

Co-Principal Investigator

University Hospital, Geneva

研究点 (1)

Loading locations...

相似试验